Departure of Chief Financial Officer

Silence Therapeutics announces departure of Chief Financial Officer

January 9, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces the departure of Mr. David Ellam, its Chief Financial Officer, with immediate effect. Dr Rob Quinn, Silence Therapeutics' Group Head of Financial Planning and Analysis will serve as interim CFO until a new CFO is appointed.

Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:

"On behalf of the Board I would like to thank David for his contribution to Silence. He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space. We wish David every success for the future."

Enquiries:

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/